Drugs / ME-015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05983471 | Apr 2024 → Aug 2025 overdue | idiopathic pulmonary fibrosis, pulmonary fibrosis | Melius Pharma AB | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05983471 ↗ |
| Route | Oral | “administered as oral capsules” NCT05983471 ↗ |